{
	"slug": "supratherapeutic-INR",
	"title": "Supratherapeutic INR",
	"authors": [
		"Michelle Lin, MD"
	],
	"created": "2012/08/10",
	"updates": null,
	"categories": [
		"Hematology and Oncology"
	],
	"body": "\n\n\n**ACCP treatment guidelines for managing supratherapeutic INR (2012, 9th ed)**\n\n|         INR | Therapeutic Intervention                                                                                                                                                                                                                      |\n| ----------: | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- |\n|      &le;10 | **_If no bleeding:_** Hold <span class=\"drug\">coumadin</span>. Restart when INR is therapeutic                                                                                                                                                |\n|      &gt;10 | **_If no bleeding:_** Hold <span class=\"drug\">coumadin</span>. Give oral <span class=\"drug\">vitamin K</span> (2.5 mg)                                                                                                                         |\n| Major bleed | Hold <span class=\"drug\">coumadin</span>. Give <span class=\"drug\">vitamin K</span> (5-10 mg slow IVP), 4-factor <span class=\"drug\">PCC</span> (<span class=\"drug\">FFP</span> not of added benefit with 4-factor <span class=\"drug\">PCC</span>) |\n\n**Higher bleeding risk associated with coumadin**\n\n- NSAIDS: non-selective and COX-2 selective\n- Antiplatelet agents: <span class=\"drug\">aspirin</span>, <span class=\"drug\">clopidogrel</span>\n- <span class=\"drug\">Clotrimoxazole</span>\n- Antibiotics (especially <span class=\"drug\">fluoroquinolones</span>)\n\n**Pearl**\n\n- Risk of intracranial hemorrhage doubles for every 1-point increase in INR\n\n## Causes for supratherapeutic INR >6\n\n[Hylek et al. JAMA 1998 study](https://www.ncbi.nlm.nih.gov/pubmed/9496982)\n\n- Retrospective case-control study of patients with INR >6\n- Enrolled 93 cases, 196 controls\n\n<table>\n<colgroup>\n<col width=\"50%\" />\n<col width=\"50%\" />\n</colgroup>\n<thead>\n<tr class=\"header\">\n<th><strong>Risk Factor / Explanation</strong></th>\n<th><strong>Odds Ratio</strong></th>\n</tr>\n</thead>\n<tbody>\n<tr class=\"odd\">\n<td>Advanced malignancy</td>\n<td>16.4</td>\n</tr>\n<tr class=\"even\">\n<td><strong></strong>\n<p><span class=\"drug\">Acetaminophen intake</span><br/> • 4.5-9.1 g/wk<br />\n• &gt; 9.1 g/wk</p></td>\n<td>6.8<br />\n10<br /></td>\n</tr>\n<tr class=\"odd\">\n<td>New medication</td>\n<td>8.5</td>\n</tr>\n<tr class=\"even\">\n<td>Excess <span class=\"drug\">coumadin</span> intake</td>\n<td>8.1</td>\n</tr>\n<tr class=\"odd\">\n<td>Decreased oral intake</td>\n<td>3.6</td>\n</tr>\n<tr class=\"even\">\n<td>Acute diarrheal illness</td>\n<td>3.5</td>\n</tr>\n<tr class=\"odd\">\n<td>Vitamin K intake</td>\n<td>0.7</td>\n</tr>\n<tr class=\"even\">\n<td>Alcohol use<br />\n(1 drink QOD-2 drinks daily)</td>\n<td>0.2</td>\n</tr>\n</tbody>\n</table>\n\n## References\n\n- Hylek EM, Heiman H, Skates SJ, Sheehan MA, Singer DE. Acetaminophen and other risk factors for excessive warfarin anticoagulation. JAMA. 1998 Mar 4;279(9):657-62 [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/9496982)]\n- Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ, Svensson PJ, Veenstra DL, Crowther M, Guyatt GH; American College of Chest Physicians.Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.Chest. 2012 Feb;141(2 Suppl):e152S-84S. doi: 10.1378/chest.11-2295. [[PubMed](https://www.ncbi.nlm.nih.gov/pubmed/22315259)]\n"
}